What's breaking now, across thousands of outlets.
Lower middle market bets and a collateral sale headline this quarter's update.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Boehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk of cardiovascular events like heart…
The week began with one of the biggest fuel price drops in Portugal since March, 9 to 9.5 cents on petrol and diesel, but it would have been bigger had the government not reduced the ISP discount.
An AI-driven bull market means a heavy tech bias at an index level.
High-yield dividend stocks can burn your portfolio, but these blue chip stocks stand out.
The loss of his Republican Party majority to the Democratic Party in the U.S. Senate and the House of Representatives in the 2026 U.S.
SM Prime Holdings Inc. of the Sy family plans to remain deliberate in its capital spending next year, as weaker real estate sales amid higher borrowing costs, elevated inflation and cautious consumer…
